| Siddhartha Sen, MBBS | |
|
2450 Riverside Ave, Minneapolis, MN 55454-1450 | |
| (612) 672-6000 | |
| Not Available |
| Full Name | Siddhartha Sen |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 23 Years |
| Location | 2450 Riverside Ave, Minneapolis, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538513684 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 69014 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Minnesota Medical Center, Fairview | Minneapolis, MN | Hospital |
| Healtheast St John's Hospital | Maplewood, MN | Hospital |
| Fairview Southdale Hospital | Edina, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fairview Express Care | 3375645179 | 1523 |
News Archive
Celldex Therapeutics, Inc. today announced that mature results from a Phase 1/2 study evaluating CDX-011 in advanced stage breast cancer patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-011 is an experimental antibody-drug conjugate (ADC) directed against glycoprotein NMB (GPNMB) and linked to a potent cancer cell-killing drug, monomethyl-auristatin E (MMAE).
A team of researchers led by Baylor College of Medicine has identified a protein called NLRC5, a member of the NOD-like protein family, that is involved in inhibition of protein complexes key to critical pathways of innate immunity called NF-κB and type I interferon signaling. A report on their work appears in the current issue of the journal Cell.
A new University of Illinois study shows that exercise-trained mice get far fewer gallstones than sedentary mice and identifies potential mechanisms to explain why this occurs.
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).
Findings in patients with bipolar disorder given short-term antidepressant treatment support the recent International Society for Bipolar Disorder's task force recommendations.
› Verified 4 days ago
| Entity Name | University Of Minnesota Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477598118 PECOS PAC ID: 9830001189 Enrollment ID: O20031104000532 |
News Archive
Celldex Therapeutics, Inc. today announced that mature results from a Phase 1/2 study evaluating CDX-011 in advanced stage breast cancer patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-011 is an experimental antibody-drug conjugate (ADC) directed against glycoprotein NMB (GPNMB) and linked to a potent cancer cell-killing drug, monomethyl-auristatin E (MMAE).
A team of researchers led by Baylor College of Medicine has identified a protein called NLRC5, a member of the NOD-like protein family, that is involved in inhibition of protein complexes key to critical pathways of innate immunity called NF-κB and type I interferon signaling. A report on their work appears in the current issue of the journal Cell.
A new University of Illinois study shows that exercise-trained mice get far fewer gallstones than sedentary mice and identifies potential mechanisms to explain why this occurs.
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).
Findings in patients with bipolar disorder given short-term antidepressant treatment support the recent International Society for Bipolar Disorder's task force recommendations.
› Verified 4 days ago
| Entity Name | Fairview Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013994359 PECOS PAC ID: 1951213057 Enrollment ID: O20031105000461 |
News Archive
Celldex Therapeutics, Inc. today announced that mature results from a Phase 1/2 study evaluating CDX-011 in advanced stage breast cancer patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-011 is an experimental antibody-drug conjugate (ADC) directed against glycoprotein NMB (GPNMB) and linked to a potent cancer cell-killing drug, monomethyl-auristatin E (MMAE).
A team of researchers led by Baylor College of Medicine has identified a protein called NLRC5, a member of the NOD-like protein family, that is involved in inhibition of protein complexes key to critical pathways of innate immunity called NF-κB and type I interferon signaling. A report on their work appears in the current issue of the journal Cell.
A new University of Illinois study shows that exercise-trained mice get far fewer gallstones than sedentary mice and identifies potential mechanisms to explain why this occurs.
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).
Findings in patients with bipolar disorder given short-term antidepressant treatment support the recent International Society for Bipolar Disorder's task force recommendations.
› Verified 4 days ago
| Entity Name | Fairview Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346432218 PECOS PAC ID: 7113830142 Enrollment ID: O20031106000516 |
News Archive
Celldex Therapeutics, Inc. today announced that mature results from a Phase 1/2 study evaluating CDX-011 in advanced stage breast cancer patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-011 is an experimental antibody-drug conjugate (ADC) directed against glycoprotein NMB (GPNMB) and linked to a potent cancer cell-killing drug, monomethyl-auristatin E (MMAE).
A team of researchers led by Baylor College of Medicine has identified a protein called NLRC5, a member of the NOD-like protein family, that is involved in inhibition of protein complexes key to critical pathways of innate immunity called NF-κB and type I interferon signaling. A report on their work appears in the current issue of the journal Cell.
A new University of Illinois study shows that exercise-trained mice get far fewer gallstones than sedentary mice and identifies potential mechanisms to explain why this occurs.
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).
Findings in patients with bipolar disorder given short-term antidepressant treatment support the recent International Society for Bipolar Disorder's task force recommendations.
› Verified 4 days ago
| Entity Name | Healtheast Medical Research Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639125503 PECOS PAC ID: 3971407636 Enrollment ID: O20031124000507 |
News Archive
Celldex Therapeutics, Inc. today announced that mature results from a Phase 1/2 study evaluating CDX-011 in advanced stage breast cancer patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-011 is an experimental antibody-drug conjugate (ADC) directed against glycoprotein NMB (GPNMB) and linked to a potent cancer cell-killing drug, monomethyl-auristatin E (MMAE).
A team of researchers led by Baylor College of Medicine has identified a protein called NLRC5, a member of the NOD-like protein family, that is involved in inhibition of protein complexes key to critical pathways of innate immunity called NF-κB and type I interferon signaling. A report on their work appears in the current issue of the journal Cell.
A new University of Illinois study shows that exercise-trained mice get far fewer gallstones than sedentary mice and identifies potential mechanisms to explain why this occurs.
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).
Findings in patients with bipolar disorder given short-term antidepressant treatment support the recent International Society for Bipolar Disorder's task force recommendations.
› Verified 4 days ago
| Entity Name | Fairview Express Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053952606 PECOS PAC ID: 3375645179 Enrollment ID: O20081028000548 |
News Archive
Celldex Therapeutics, Inc. today announced that mature results from a Phase 1/2 study evaluating CDX-011 in advanced stage breast cancer patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-011 is an experimental antibody-drug conjugate (ADC) directed against glycoprotein NMB (GPNMB) and linked to a potent cancer cell-killing drug, monomethyl-auristatin E (MMAE).
A team of researchers led by Baylor College of Medicine has identified a protein called NLRC5, a member of the NOD-like protein family, that is involved in inhibition of protein complexes key to critical pathways of innate immunity called NF-κB and type I interferon signaling. A report on their work appears in the current issue of the journal Cell.
A new University of Illinois study shows that exercise-trained mice get far fewer gallstones than sedentary mice and identifies potential mechanisms to explain why this occurs.
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).
Findings in patients with bipolar disorder given short-term antidepressant treatment support the recent International Society for Bipolar Disorder's task force recommendations.
› Verified 4 days ago
| Entity Name | University Of Minnesota Health Clinics And Surgery Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053795187 PECOS PAC ID: 9133423304 Enrollment ID: O20160209000524 |
News Archive
Celldex Therapeutics, Inc. today announced that mature results from a Phase 1/2 study evaluating CDX-011 in advanced stage breast cancer patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-011 is an experimental antibody-drug conjugate (ADC) directed against glycoprotein NMB (GPNMB) and linked to a potent cancer cell-killing drug, monomethyl-auristatin E (MMAE).
A team of researchers led by Baylor College of Medicine has identified a protein called NLRC5, a member of the NOD-like protein family, that is involved in inhibition of protein complexes key to critical pathways of innate immunity called NF-κB and type I interferon signaling. A report on their work appears in the current issue of the journal Cell.
A new University of Illinois study shows that exercise-trained mice get far fewer gallstones than sedentary mice and identifies potential mechanisms to explain why this occurs.
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).
Findings in patients with bipolar disorder given short-term antidepressant treatment support the recent International Society for Bipolar Disorder's task force recommendations.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Siddhartha Sen, MBBS 420 Delaware St Se, Minneapolis, MN 55455-0341 Ph: (612) 273-3552 | Siddhartha Sen, MBBS 2450 Riverside Ave, Minneapolis, MN 55454-1450 Ph: (612) 672-6000 |
News Archive
Celldex Therapeutics, Inc. today announced that mature results from a Phase 1/2 study evaluating CDX-011 in advanced stage breast cancer patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-011 is an experimental antibody-drug conjugate (ADC) directed against glycoprotein NMB (GPNMB) and linked to a potent cancer cell-killing drug, monomethyl-auristatin E (MMAE).
A team of researchers led by Baylor College of Medicine has identified a protein called NLRC5, a member of the NOD-like protein family, that is involved in inhibition of protein complexes key to critical pathways of innate immunity called NF-κB and type I interferon signaling. A report on their work appears in the current issue of the journal Cell.
A new University of Illinois study shows that exercise-trained mice get far fewer gallstones than sedentary mice and identifies potential mechanisms to explain why this occurs.
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).
Findings in patients with bipolar disorder given short-term antidepressant treatment support the recent International Society for Bipolar Disorder's task force recommendations.
› Verified 4 days ago
Khalid Amin, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 420 Delaware St Se, C463 Mayo Memorial Bldg, Mayo Mail Code 76, Minneapolis, MN 55455 Phone: 913-827-3505 | |
Dr. Laura L Schmitz, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Minneapolis, MN 55422 Phone: 763-581-4150 Fax: 763-581-4151 | |
Dr. Michael Patrick Greenwood, MD Pathology Medicare: Medicare Enrolled Practice Location: 909 Fulton St Se, Minneapolis, MN 55455 Phone: 612-672-7422 | |
Deborah Elizabeth Powell, MD Pathology Medicare: Medicare Enrolled Practice Location: 500 Harvard St Se, Lab Med & Pathology, Minneapolis, MN 55455 Phone: 612-273-1142 | |
Yiang Hui, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2800 10th Ave S Ste 2200, Minneapolis, MN 55407 Phone: 612-767-8373 | |
Dr. Pamela Ann Sakkinen, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2800 10th Ave S Ste 2200, Hospital Pathology Assoc, Minneapolis, MN 55407 Phone: 612-767-8370 Fax: 612-767-8376 | |
Kevin Todd Stieglbauer, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2800 10th Ave S Ste 2200, Hospital Pathology Assoc, Minneapolis, MN 55407 Phone: 612-767-8370 Fax: 612-767-8376 |